Abstract:Background Spinal cord injury (SCI) is a severe neurological disorder with many disabling consequences, including persistent neuropathic pain, which develops in about 40 % of SCI patients and is induced and sustained by excessive and uncontrolled spinal neuroinflammation. Here, we have evaluated the effects of lipoxin A4 (LXA4), a member of a unique class of endogenous lipid mediators with both anti-inflammatory and analgesic properties, on spinal neuroinflammation and chronic pain in an experimental model of SCI. Methods Spinal hemisection at T10 was carried out in adult male CD1 mice and Wistar rats. To test if LXA4 can reduce neuroinflammation and neuropathic pain, each animal received two intrathecal injections of LXA4 (300 pmol) or vehicle at 4 and 24 h after SCI. Sensitivity to mechanical stimulation of the hind paws was evaluated using von Frey monofilaments, and neuroinflammation was tested by measuring the mRNA and/or protein expression levels of glial markers and cytokines in the spinal cord samples after SCI. Also, microglia cultures prepared from murine cortical tissue were used to assess the direct effects of LXA4 on microglial activation and release of pro-inflammatory TNF-α. Results LXA4 treatment caused significant reductions in the intensity of mechanical pain hypersensitivity and spinal expression levels of microglial markers and pro-inflammatory cytokines induced by SCI, when compared to rodents receiving control vehicle injections. Notably, the increased expressions of the microglial marker IBA-1 and of the pro-inflammatory cytokine TNF-α were the most affected by the LXA4 treatment. Furthermore, cortical microglial cultures expressed ALX/FPR2 receptors for LXA4 and displayed potentially anti-inflammatory responses upon challenge with LXA4. Conclusions Collectively, our results suggest that LXA4 can effectively modulate microglial activation and TNF-α release through ALX/FPR2 receptors, ultimately reducing neuropathic pain in rodents after spinal cord hemisection. The dual anti-inflammatory and analgesic properties of LXA4, allied to its endogenous nature and safety profile, may render this lipid mediator as new therapeutic approach for treating various neuroinflammatory disorders and chronic pain with only limited side effects.

Neuroprotective Effect of Lipoxin A 4 Methyl Ester in a Rat Model of Permanent Focal Cerebral Ischemia

The protective effect of lipoxin A4 in a rat model of permanent focal cerebral ischemia

Lipoxin A4 Analogue Protects Brain and Reduces Inflammation in a Rat Model of Focal Cerebral Ischemia Reperfusion.

Effect of lipoxin A4 on inflammatory response in a rat model of permanent focal cerebral ischemia

Effects of Lipoxin A4 on Inflammatory Response to Focal Cerebral Ischemia-Reperfusion Injury in Rats

Protective effects of lipoxin A4 on focal brain ischemia reperfusion injury in rats

Effect of lipoxin A4 on permeability of blood-brain barrier after focal cerebral ischemia-reperfusion in rats

A Lipoxin A 4 Analog Ameliorates Blood–Brain Barrier Dysfunction and Reduces MMP-9 Expression in a Rat Model of Focal Cerebral Ischemia–Reperfusion Injury

Lipoxin A4 Methyl Ester Reduces Early Brain Injury by Inhibition of the Nuclear Factor Kappa B (Nf-Κb)-dependent Matrix Metallopeptidase 9 (MMP-9) Pathway in a Rat Model of Intracerebral Hemorrhage

Lipoxin A 4 Inhibits 5-Lipoxygenase Translocation and Leukotrienes Biosynthesis to Exert a Neuroprotective Effect in Cerebral Ischemia/Reperfusion Injury

Lipoxin A4 Ameliorates Cerebral Ischaemia/reperfusion Injury Through Upregulation of Nuclear Factor Erythroid 2-Related Factor 2.

Lipoxin A(4) Methyl Ester Alleviates Vascular Cognition Impairment by Regulating the Expression of Proteins Related to Autophagy and Er Stress in the Rat Hippocampus

Effects of Lipoxin A4 Pretreatment on Cognitive Function of Aged Rats after Global Cerebral Ischemia Reperfusion

LXA4 Ameliorates Cerebrovascular Endothelial Dysfunction by Reducing Acute Inflammation after Subarachnoid Hemorrhage in Rats

Lipoxin A4 inhibits microglial activation and reduces neuroinflammation and neuropathic pain after spinal cord hemisection

LXA4 protects against hypoxic-ischemic damage in neonatal rats by reducing the inflammatory response via the IκB/NF-κB pathway

Lipoxin A4 Reduces Inflammation Through Formyl Peptide Receptor 2/p38 MAPK Signaling Pathway in Subarachnoid Hemorrhage Rats

Neuronal Injury in Rat Model of Permanent Focal Cerebral Ischemia is Associated with Activation of Autophagic and Lysosomal Pathways.

Phosphodiesterase-4 Inhibition Confers a Neuroprotective Efficacy Against Early Brain Injury Following Experimental Subarachnoid Hemorrhage in Rats by Attenuating Neuronal Apoptosis Through the SIRT1/Akt Pathway.

Anti-inflammatory effects of lipoxin A4 in cerebral ischemia

Lipoxin A 4 Reduces Inflammation Through Formyl Peptide Receptor 2 / p 38 MAPK Signaling Pathway in Subarachnoid Hemorrhage Rats